Silexion Plunges 12.99% Amid Share Capital Increase Vote

On August 1, 2025, Silexion's stock price dropped by 12.99% in pre-market trading, marking a significant decline for the biotechnology company.

Silexion recently secured $1.8 million through a warrant exercise, strengthening its RNAi therapy development for KRAS-driven cancers. The new warrants were issued at $11.32 per share, providing the company with additional financial resources to advance its innovative treatments.

Silexion is also preparing for an extraordinary general meeting on August 12, 2025, to seek shareholder approval for an increase in its authorized share capital. This proposal aims to enable the company to maintain its Nasdaq listing and fund its pre-clinical and clinical development programs. The meeting will be held both in person and virtually, allowing shareholders to participate and vote on the proposal.

The company's board of directors has recommended a vote "FOR" the Authorized Share Capital Increase Proposal, highlighting the importance of maintaining Nasdaq compliance and supporting the development of its RNAi therapies. The proposal, if approved, will increase the authorized share capital from US$20,000 to US$121,500, divided into 9,000,000 ordinary shares.